Tadalafil therapy and health-related quality of life in pulmonary arterial hypertension

Current Medical Research and Opinion

Volumn 25, Issue 10, 2009, Pages 2479-2485

  Pepke Zaba, Joanna ^a   Beardsworth, Anthony ^b   Chan, Melanie ^b   Angalakuditi, Mallik ^b  

^a PAPWORTH HOSPITAL   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Adcirca; Hypertension, pulmonary; Patient outcomes assessment; Quality of life; Tadalafil

Indexed keywords

BOSENTAN; PLACEBO; TADALAFIL;

ANTIHYPERTENSIVE THERAPY; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EXERCISE; FEMALE; HEADACHE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; PHYSICAL CAPACITY; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SCORING SYSTEM; SHORT FORM 36;

CARBOLINES; DOUBLE-BLIND METHOD; EXERCISE TEST; HUMANS; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE INHIBITORS; PLACEBOS; QUALITY OF LIFE;

EID: 70349327721     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903210066     Document Type: Article

References (22)

1. Simonneau G, Galié N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43:5-12S
2. Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol 2008;51:1527-1538
3. Humbert M, Sitbon O, Simmoneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-1436
4. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004;351:1655-1665
5. Frost AE, Badesch DB, Barst RJ, et al. A comparison of REVEAL registry demographic data with other/prior registries of pulmonary arterial hypertension (PAH). Chest Meeting Abstracts 2008;134:p134001
6. Badesch DB, Abman SH, Simmoneau G, et al. Medical therapy for pulmonary arterial hypertension. Updated ACCP Evidence-Based Clinical Practice Guidelines. Chest 2007;131:1917-1928
7. Thenappan T, Shah SJ, Rich S, et al. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J 2007;30:1103-1110
8. Enright PL. The six-minute walk test. Respir Care 2003;48:783-785
9. Macchia A, Marchioli R, Marfisi R, et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 2007;153:1037-1047 (Pubitemid 46809838)
10. Galiè N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009;30:394-403
11. Ware JEJ, Kosinski M, Gandek B. SF-36® Health Survey: Manual & Interpretation Guide, 2nd edn. Lincoln, RI: Qualitymetric, Inc, 2000
12. Johnson JA, Coons SJ, Ergo A, et al. Valuation of EuroQOL (EQ-5D) health states in an adult US sample. Pharmacoeconomics 1998;13:421-433 (Pubitemid 28140701)
13. Rabin R. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337-343 (Pubitemid 32675374)
14. Chen H, Taichman DB, Doyle RL. Health-related quality of life and patient-reported outcomes in pulmonary arterial hypertension. Proc Am Thorac Soc 2008;5:623-630 (Pubitemid 352031535)
15. Pepke-Zaba J, Gilbert C, Collings L, et al. Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension. Chest 2008;133:183-189
16. Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117:3010-3019
17. Olschewski H, Simonneau G, Galié N, et al.; for the Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-329 (Pubitemid 34252285)
18. Rector RS, Kubo SH, Cohn JN. Patients' self-assessment of their congestive heart failure. Heart Fail 1987;1:198-209
19. Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil for pulmonary arterial hypertension therapy. Circulation 2009 May 26 [Epub ahead of print] (Pubitemid 41653106)
20. McKenna SP, Doughty N, Meads DM, et al. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): A measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res 2006;15:103-115 (Pubitemid 43097591)
21. Gomberg-Maitland M, Thenappan T, Rizvi K, et al. United States validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). J Heart Lung Transplant 2008;27:124-130
22. Meads DM, McKenna SP, Doughty N, et al. The responsiveness and validity of the CAMPHOR Utility Index. Eur Respir J 2008;32:1513-1519